Loading
A phase 1 trial of CI-8993 run by Janssen Research & Development, LLC, terminated.
A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer is a phase 1 interventional study registered as NCT02671955 by Janssen Research & Development, LLC, with 12 participants enrolled, started 2016-01. Conditions recorded: Advanced Cancer. Interventions recorded: JNJ-61610588.
Shares ImmuNext, CI-8993, Curis, Johnson & Johnson and the tag pipeline.
Shares Johnson & Johnson, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Curis and the tag pipeline.
Shares Curis and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/